585 lines
No EOL
28 KiB
HTML
585 lines
No EOL
28 KiB
HTML
<!-- Changed ON 09/24/2024 -->
|
|
<!-- Google Tag Manager -->
|
|
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
|
|
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
|
|
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
|
|
'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
|
|
})(window,document,'script','dataLayer','GTM-T2DH393N');</script>
|
|
<!-- End Google Tag Manager -->
|
|
|
|
|
|
|
|
|
|
|
|
<HTML lang="en-US">
|
|
<HEAD>
|
|
<!-- From DocTemplateOld.txt -->
|
|
|
|
|
|
|
|
|
|
<TITLE>Expired PA-02-015: ROLE OF LIMBIC SYSTEM AND BRAIN ONTOGENY IN DRUG ABUSE</TITLE>
|
|
|
|
|
|
<META NAME="description" CONTENT="NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: ROLE OF LIMBIC SYSTEM AND BRAIN ONTOGENY IN DRUG ABUSE PA-02-015. NIDA">
|
|
<META NAME="Keywords" CONTENT="PA-02-015: ROLE OF LIMBIC SYSTEM AND BRAIN ONTOGENY IN DRUG ABUSE">
|
|
|
|
</HEAD>
|
|
|
|
<BODY BGCOLOR="#FFFFFF" TEXT="#000000">
|
|
|
|
|
|
<link type="text/css" href="../guide_styles/css/oldGuideStyle.css" rel="stylesheet" media="all">
|
|
<link type="text/css" href="../guide_styles/css/expired.css" rel="stylesheet" media="all">
|
|
<div class="noticeBar">This notice has expired. Check the <a href="https://grants.nih.gov/funding/searchguide/">NIH Guide</a> for active opportunities and notices.</div>
|
|
<div id="watermark_background">
|
|
<p id="watermark_text">EXPIRED</p>
|
|
</div>
|
|
<pre>
|
|
|
|
This Program Announcement (PA) expires on October 31, 2004, unless reissued.
|
|
|
|
ROLE OF LIMBIC SYSTEM AND BRAIN ONTOGENY IN DRUG ABUSE
|
|
|
|
Release Date: October 19, 2001
|
|
|
|
PA NUMBER: PA-02-015
|
|
|
|
<a href="//grants.nih.gov/grants/guide/notice-files/NOT-OD-06-046.html">March 2, 2006</a> (NOT-OD-06-046) Effective with the June 1, 2006 submission date,
|
|
all R03, R21, R33 and R34 applications must be submitted through <a href="http://www.grants.gov/">Grants.gov</a> using
|
|
the electronic SF424 (R&R) application. A Replacement R21 (<a href="//grants.nih.gov/grants/guide/pa-files/PA-06-445.html">PA-06-445</a>) funding
|
|
opportunity announcement has been issued for the submission date of June 1, 2006
|
|
and submission dates thereafter. In addition, a replacement R01 (<a href="//grants.nih.gov/grants/guide/pa-files/PA-06-444.html">PA-06-444</a>) has
|
|
been issued.
|
|
|
|
EXPIRATION DATE: October 31, 2004
|
|
|
|
National Institute on Drug Abuse
|
|
(<a href="http://www.nida.nih.gov">http://www.nida.nih.gov</a>)
|
|
|
|
THIS PA USES "MODULAR GRANT" AND "JUST-IN-TIME" CONCEPTS. MODULAR
|
|
INSTRUCTIONS MUST BE USED FOR RESEARCH GRANT APPLICATIONS UP TO
|
|
$250,000 PER YEAR. MODULAR BUDGET INSTRUCTIONS ARE PROVIDED IN SECTION
|
|
C OF THE PHS 398 (REVISION 5/2001) AVAILABLE AT
|
|
<a href="//grants.nih.gov/grants/funding/phs398/phs398.html">http://grants.nih.gov/grants/funding/phs398/phs398.html</a>.
|
|
|
|
PURPOSE
|
|
|
|
This version will replace in its entirety, PA-98-032, Role of Limbic
|
|
System and Brain Ontogeny in Drug Abuse, published in the NIH Guide
|
|
February 25, 1998.
|
|
|
|
Specific cortical and subcortical forebrain structures, often referred
|
|
to as the limbic system, play a significant role in mediating emotional
|
|
and motivated behavior as well as memory storage. The proper
|
|
development of forebrain structures and the formation of neural
|
|
circuitry in the forebrain are essential for the normal development of
|
|
pathways that mediate the hedonic properties of food, sex, and drugs of
|
|
abuse. Elucidation of the processes underlying the development of the
|
|
limbic system may provide critical insights into the adaptive processes
|
|
associated with addiction and provide insights into mechanisms that
|
|
might underlie increased vulnerability to addiction. This initiative
|
|
is designed to support basic research into the fundamental mechanisms
|
|
of development of the midbrain and basal forebrain structures that
|
|
mediate the euphoric properties of drugs as well as understanding how
|
|
drugs of abuse affect the cellular and molecular mechanism underlying
|
|
nervous system development. In the past, vertebrate model systems
|
|
(such as chick, frog, mouse, and zebrafish) and invertebrate systems
|
|
(such as Drosophila and C. Elegans) have provided insights into
|
|
mechanisms of development and are also likely to provide new
|
|
information about the formation and specification of the limbic system.
|
|
Approaches using these or other model systems both in vitro and in vivo
|
|
are applicable to this program announcement.
|
|
|
|
HEALTHY PEOPLE 2010
|
|
|
|
The Public Health Service (PHS) is committed to achieving the health
|
|
promotion and disease prevention objectives of "Healthy People 2010," a
|
|
PHS led national activity for setting priority areas. This PA, Role of
|
|
Limbic System and Brain Ontogeny in Drug Abuse, is related to one or
|
|
more of the priority areas. Potential applicants may obtain a copy of
|
|
"Healthy People 2010" at <a href="https://www.health.gov/healthypeople/">http://www.health.gov/healthypeople/</a>.
|
|
|
|
ELIGIBILITY REQUIREMENTS
|
|
|
|
Applications may be submitted by domestic and foreign, for-profit and
|
|
non-profit organizations, public and private, such as, universities,
|
|
colleges, hospitals, laboratories, units of state and local
|
|
governments, and eligible agencies of the Federal government.
|
|
Racial/ethnic minority individuals, women, and persons with
|
|
disabilities are encouraged to apply as principal investigators.
|
|
|
|
MECHANISM OF SUPPORT
|
|
|
|
This PA will use the National Institutes of Health (NIH) research
|
|
project grant (R01) and exploratory/developmental grant (R21) award
|
|
mechanisms. Responsibility for the planning, direction, and execution
|
|
of the proposed project will be solely that of the applicant. The
|
|
research project grant (R01) application may not exceed 5 years. An
|
|
exploratory/developmental (R21) application is limited to 3 years. The
|
|
R21 mechanism is intended to encourage exploratory research projects
|
|
with sound methodology and strong rationales in underdeveloped areas of
|
|
drug abuse, and is limited in direct cost amounts of $100,000 per year.
|
|
Specific information on this research mechanism can be obtained from
|
|
NIDA’s homepage (www.nida.nih.gov/funding.html).
|
|
|
|
Specific application instructions have been modified to reflect
|
|
"MODULAR GRANT" and "JUST-IN-TIME" streamlining efforts that have been
|
|
adopted by the NIH. Complete and detailed instructions and information
|
|
on Modular Grant applications have been incorporated into the PHS 398
|
|
(rev. 5/2001). Additional information on Modular Grants can be found
|
|
at <a href="//grants.nih.gov/grants/funding/modular/modular.htm">http://grants.nih.gov/grants/funding/modular/modular.htm</a>.
|
|
|
|
RESEARCH OBJECTIVES
|
|
|
|
Examples of research that may be considered responsive to this program
|
|
announcement include, but are not limited to, those listed below. In
|
|
all research areas, investigators are encouraged to analyze
|
|
developmental mechanisms that contribute to sexual dimorphisms.
|
|
|
|
Neural Induction and Pattern Formation.
|
|
|
|
o Studies on the cellular and molecular mechanisms by which the
|
|
midbrain, nucleus accumbens, striatum, prefrontal cortex and limbic
|
|
area are specified from neural ectoderm including regionalization of
|
|
gene transcription, cell-cell interaction, and secreted signals that
|
|
influence these processes.
|
|
|
|
o How psychostimulants (cocaine, amphetamine, etc.), opiates,
|
|
barbiturates, hallucinogens, benzodiazepines, cannabinoids, inhalants,
|
|
and any other class of abused drugs affect the cellular and molecular
|
|
mechanisms of neural induction and pattern formation.
|
|
|
|
Stem Cells and Progenitors.
|
|
|
|
o The cellular and molecular mechanisms of stem cell and progenitor
|
|
cell induction, proliferation, and phenotypic restriction in the
|
|
midbrain, nucleus accumbens, striatum, prefrontal cortex and limbic
|
|
regions of the brain.
|
|
|
|
o Studies on how abused drugs influence fundamental processes
|
|
controlling stem cell, progenitor cell induction, and phenotypic
|
|
restriction in all parts of the nervous system.
|
|
|
|
Cell Fate and Specification.
|
|
|
|
o The mechanisms by which neuronal and glial cell fate is specified by
|
|
cell-cell interaction, growth factor, cytokines, hormones, and by
|
|
neurotransmitters in the midbrain, nucleus accumbens, striatum,
|
|
prefrontal cortex, and limbic regions.
|
|
|
|
o How drugs of abuse modulate the molecular mechanisms are involved in
|
|
determining cell fate and specifications in all brain regions.
|
|
|
|
Neural and Glial Differentiation.
|
|
|
|
o The transcriptional and post-transcriptional regulation of the
|
|
acquisition of the differentiated phenotype of dopamine neurons in the
|
|
ventral tegmental area and substantia nigra, as well as neurons and
|
|
glia in the midbrain, nucleus accumbens, striatum, prefrontal cortex,
|
|
and limbic areas (including cell morphology, excitability, growth
|
|
factor responsiveness, and expression of neurotransmitters and
|
|
receptors).
|
|
|
|
o The molecular and cellular processes by which drugs of abuse alter
|
|
neuronal differentiation by interrupting or augmenting the signal
|
|
transduction mechanisms involved in the acquisition of the
|
|
differentiated neuronal and glial phenotypes in all brain regions.
|
|
|
|
Cell Migration.
|
|
|
|
o The cellular and molecular substrates that direct and guide glial
|
|
and neuronal migration in the areas that form the midbrain, nucleus
|
|
accumbens, striatum, prefrontal cortex, and limbic areas.
|
|
|
|
o How drugs of abuse modulate or alter fundamental mechanisms are
|
|
involved in cell migration in all areas of the brain.
|
|
|
|
Process Outgrowth, Navigation, and Target Selection.
|
|
|
|
o The cellular and molecular mechanisms that regulate dendritic and
|
|
axonal outgrowth, navigation, and target selection (including axonal
|
|
guidance, branching, fasciculation, the formation of topographic and
|
|
laminar-specific projections in the midbrain, nucleus accumbens,
|
|
striatum, prefrontal cortex and limbic areas).
|
|
|
|
o How drugs of abuse affect the fundamental cellular mechanisms
|
|
mediating process outgrowth, navigation, and target selection in all
|
|
areas of the brain.
|
|
|
|
Synapse Formation and Plasticity During Development.
|
|
|
|
o The cellular and molecular mechanisms governing the formation of
|
|
synapses and developmental plasticity as well as the role of cell-cell
|
|
recognition molecules, growth factors, electrical activity, and
|
|
experience in the development of the midbrain, nucleus accumbens,
|
|
striatum, prefrontal cortex, and limbic systems.
|
|
|
|
o Analysis of how abused drugs affect the cellular and molecular
|
|
mechanisms governing the formation of synapses and developmental
|
|
plasticity throughout the central and peripheral nervous system.
|
|
|
|
Programmed Cell Death.
|
|
|
|
o Investigations into the cellular and molecular mechanisms of
|
|
programmed cell death in the midbrain, nucleus accumbens, striatum,
|
|
prefrontal cortex, and limbic systems during development.
|
|
|
|
o Investigations on how abused drugs may modulate signal transduction
|
|
pathways that mediate cell survival and cell death in vertebrate and
|
|
invertebrate systems.
|
|
|
|
INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS
|
|
|
|
It is the policy of the NIH that women and members of minority groups
|
|
and their sub-populations must be included in all NIH-supported
|
|
biomedical and behavioral research projects involving human subjects,
|
|
unless a clear and compelling rationale and justification are provided
|
|
indicating that inclusion is inappropriate with respect to the health
|
|
of the subjects or the purpose of the research. This policy results
|
|
from the NIH Revitalization Act of 1993 (Section 492B of Public Law
|
|
103-43).
|
|
|
|
All investigators proposing research involving human subjects should
|
|
read the UPDATED "NIH Guidelines for Inclusion of Women and Minorities
|
|
as Subjects in Clinical Research," published in the NIH Guide for
|
|
Grants and Contracts on August 2, 2000
|
|
(<a href="//grants.nih.gov/grants/guide/notice-files/NOT-OD-00-048.html">http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-048.html</a>. A
|
|
complete copy of the updated Guidelines is available at
|
|
<a href="//grants.nih.gov/grants/funding/women_min/guidelines_update.htm">http://grants.nih.gov/grants/funding/women_min/guidelines_update.htm</a>.
|
|
The revisions relate to NIH defined Phase III clinical trials and
|
|
require: a) all applications or proposals and/or protocols to provide a
|
|
description of plans to conduct analyses, as appropriate, to address
|
|
differences by sex/gender and/or racial/ethnic groups, including
|
|
subgroups if applicable, and b) all investigators to report accrual,
|
|
and to conduct and report analyses, as appropriate, by sex/gender
|
|
and/or racial/ethnic group differences.
|
|
|
|
INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS
|
|
|
|
It is the policy of NIH that children (i.e., individuals under the age
|
|
of 21) must be included in all human subjects research, conducted or
|
|
supported by the NIH, unless there are scientific and ethical reasons
|
|
not to include them. This policy applies to all initial (Type 1)
|
|
applications submitted for receipt dates after October 1, 1998.
|
|
|
|
All investigators proposing research involving human subjects should
|
|
read the "NIH Policy and Guidelines on the Inclusion of Children as
|
|
Participants in Research Involving Human Subjects" that was published
|
|
in the NIH Guide for Grants and Contracts, March 6, 1998, and is
|
|
available at the following URL address:
|
|
<a href="//grants.nih.gov/grants/guide/notice-files/not98-024.html">http://grants.nih.gov/grants/guide/notice-files/not98-024.html</a>.
|
|
|
|
Investigators also may obtain copies of these policies from the program
|
|
staff listed under INQUIRIES. Program staff may also provide
|
|
additional relevant information concerning the policy.
|
|
|
|
REQUIRED EDUCATION ON THE PROTECTION OF HUMAN SUBJECT PARTICIPANTS
|
|
|
|
NIH policy requires education on the protection of human subject
|
|
participants for all investigators submitting NIH proposals for
|
|
research involving human subjects. This policy announcement is found
|
|
in the NIH Guide for Grants and Contracts Announcement dated June 5,
|
|
2000, at the following website:
|
|
<a href="//grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html">http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html</a>.
|
|
|
|
URLS IN NIH GRANT APPLICATIONS OR APPENDICES
|
|
|
|
All applications and proposals for NIH funding must be self-contained
|
|
within specified page limitations. Unless otherwise specified in an
|
|
NIH solicitation, Internet addresses (URLs) should not be used to
|
|
provide information necessary to the review because reviewers are under
|
|
no obligation to view the Internet sites. Reviewers are cautioned that
|
|
their anonymity may be compromised when they directly access an
|
|
Internet site.
|
|
|
|
PUBLIC ACCESS TO RESEARCH DATA THROUGH THE FREEDOM OF INFORMATION ACT
|
|
|
|
The Office of Management and Budget (OMB) Circular A-110 has been
|
|
revised to provide public access to research data through the Freedom
|
|
of Information Act (FOIA) under some circumstances. Data that are (1)
|
|
first produced in a project that is supported in whole or in part with
|
|
Federal funds and (2) cited publicly and officially by a Federal agency
|
|
in support of an action that has the force and effect of law (i.e., a
|
|
regulation) may be accessed through FOIA. It is important for
|
|
applicants to understand the basic scope of this amendment. NIH has
|
|
provided guidance at:
|
|
<a href="//grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm">http://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm</a>.
|
|
|
|
Applicants may wish to place data collected under this PA in a public
|
|
archive, which can provide protections for the data and manage the
|
|
distribution for an indefinite period of time. If so, the application
|
|
should include a description of the archiving plan in the study design
|
|
and include information about this in the budget justification section
|
|
of the application. In addition, applicants should think about how to
|
|
structure informed consent statements and other human subjects
|
|
procedures given the potential for wider use of data collected under
|
|
this award.
|
|
|
|
APPLICATION PROCEDURES
|
|
|
|
The PHS 398 research grant application instructions and forms (rev.
|
|
5/2001) at <a href="//grants.nih.gov/grants/funding/phs398/phs398.html">http://grants.nih.gov/grants/funding/phs398/phs398.html</a> must
|
|
be used in applying for these grants and will be accepted at the
|
|
standard application deadlines (<a href="//grants.nih.gov/grants/dates.htm">http://grants.nih.gov/grants/dates.htm</a>)
|
|
as indicated in the application kit. This version of the PHS 398 is
|
|
available in an interactive, searchable format. Although applicants are
|
|
strongly encouraged to begin using the 5/2001 revision of the PHS 398
|
|
as soon as possible, the NIH will continue to accept applications
|
|
prepared using the 4/1998 revision until January 9, 2002. Beginning
|
|
January 10, 2002, however, the NIH will return applications that are
|
|
not submitted on the 5/2001 version. For further assistance contact
|
|
GrantsInfo, Telephone 301/710-0267, Email: <a href="/cdn-cgi/l/email-protection#632411020d17102a0d050c230d0a0b4d040c15"><span class="__cf_email__" data-cfemail="82c5f0e3ecf6f1cbece4edc2ecebeaace5edf4">[email protected]</span></a>.
|
|
|
|
Applicants planning to submit an investigator-initiated new (type 1),
|
|
competing continuation (type 2), competing supplement, or any
|
|
amended/revised version of the preceding grant application types
|
|
requesting $500,000 or more in direct costs for any year are advised
|
|
that he or she must contact the Institute or Center (IC) program staff
|
|
before submitting the application, i.e., as plans for the study are
|
|
being developed. Furthermore, the application must obtain agreement
|
|
from the IC staff that the IC will accept the application for
|
|
consideration for award. Finally, the applicant must identify, in a
|
|
cover letter sent with the application, the staff member and Institute
|
|
or Center who agreed to accept assignment of the application.
|
|
|
|
This policy requires an applicant to obtain agreement for acceptance of
|
|
both any such application and any such subsequent amendment. Refer to
|
|
the NIH Guide for Grants and Contracts, March 20, 1998 at
|
|
<a href="//grants.nih.gov/grants/guide/notice-files/not98-030.html">http://grants.nih.gov/grants/guide/notice-files/not98-030.html</a>.
|
|
|
|
SPECIFIC INSTRUCTIONS FOR MODULAR GRANT APPLICATIONS
|
|
|
|
The modular grant concept establishes specific modules in which direct
|
|
costs may be requested as well as a maximum level for requested
|
|
budgets. Only limited budgetary information is required under this
|
|
approach. The just-in-time concept allows applicants to submit certain
|
|
information only when there is a possibility for an award. It is
|
|
anticipated that these changes will reduce the administrative burden
|
|
for the applicants, reviewers and NIH staff. The research grant
|
|
application form PHS 398 (rev. 5/2001) at
|
|
<a href="//grants.nih.gov/grants/funding/phs398/phs398.html">http://grants.nih.gov/grants/funding/phs398/phs398.html</a> is to be used
|
|
in applying for these grants, with modular budget instructions provided
|
|
in Section C of the application instructions. Applicants are
|
|
permitted, however, to use the 4/1998 revision of the PHS 398 for
|
|
scheduled application receipt dates until January 9, 2002. If you are
|
|
preparing an application using the 4/1998 version, please refer to the
|
|
step-by-step instructions for Modular Grants available at
|
|
<a href="//grants.nih.gov/grants/funding/modular/modular.htm">http://grants.nih.gov/grants/funding/modular/modular.htm</a>. Additional
|
|
information about Modular Grants is also available on this site.
|
|
|
|
The title and number of the program announcement must be typed on line
|
|
2 of the face page of the application form and the YES box must be
|
|
marked.
|
|
|
|
Submit a signed, typewritten original of the application, including the
|
|
Checklist, and five signed photocopies in one package to:
|
|
|
|
CENTER FOR SCIENTIFIC REVIEW
|
|
NATIONAL INSTITUTES OF HEALTH
|
|
6701 ROCKLEDGE DRIVE, ROOM 1040, MSC 7710
|
|
BETHESDA, MD 20892-7710
|
|
BETHESDA, MD 20817 (for express/courier service)
|
|
|
|
REVIEW CONSIDERATIONS
|
|
|
|
Applications will be assigned on the basis of established PHS referral
|
|
guidelines. Applications will be evaluated for scientific and
|
|
technical merit by an appropriate scientific review group convened in
|
|
accordance with the standard NIH peer review procedures. As part of
|
|
the initial merit review, all applications will receive a written
|
|
critique and undergo a process in which only those applications deemed
|
|
to have the highest scientific merit, generally the top half of
|
|
applications under review, will be discussed, assigned a priority
|
|
score, and receive a second level review by the appropriate national
|
|
advisory council or board.
|
|
|
|
Review Criteria
|
|
|
|
The goals of NIH-supported research are to advance our understanding of
|
|
biological systems, improve the control of disease, and enhance health.
|
|
In the written comments reviewers will be asked to discuss the
|
|
following aspects of the application in order to judge the likelihood
|
|
that the proposed research will have a substantial impact on the
|
|
pursuit of these goals. Each of these criteria will be addressed and
|
|
considered in assigning the overall score, weighting them as
|
|
appropriate for each application. Note that the application does not
|
|
need to be strong in all categories to be judged likely to have major
|
|
scientific impact and thus deserve a high priority score. For example,
|
|
an investigator may propose to carry out important work that by its
|
|
nature is not innovative but is essential to move a field forward.
|
|
|
|
(1) Significance: Does this study address an important problem? If
|
|
the aims of the application are achieved, how will scientific knowledge
|
|
be advanced? What will be the effect of these studies on the concepts
|
|
or methods that drive this field?
|
|
|
|
(2) Approach: Are the conceptual framework, design, methods, and
|
|
analyses adequately developed, well-integrated, and appropriate to the
|
|
aims of the project? Does the applicant acknowledge potential problem
|
|
areas and consider alternative tactics?
|
|
|
|
(3) Innovation: Does the project employ novel concepts, approaches or
|
|
method? Are the aims original and innovative? Does the project
|
|
challenge existing paradigms or develop new methodologies or
|
|
technologies?
|
|
|
|
(4) Investigator: Is the investigator appropriately trained and well
|
|
suited to carry out this work? Is the work proposed appropriate to the
|
|
experience level of the principal investigator and other researchers
|
|
(if any)?
|
|
|
|
(5) Environment: Does the scientific environment in which the work
|
|
will be done contribute to the probability of success? Do the proposed
|
|
experiments take advantage of unique features of the scientific
|
|
environment or employ useful collaborative arrangements? Is there
|
|
evidence of institutional support?
|
|
|
|
In addition to the above criteria, in accordance with NIH policy, all
|
|
applications will also be reviewed with respect to the following:
|
|
|
|
o The adequacy of plans to include both genders, minorities and their
|
|
subgroups, and children as appropriate for the scientific goals of the
|
|
research. Plans for the recruitment and retention of subjects will
|
|
also be evaluated.
|
|
|
|
o The reasonableness of the proposed budget and duration in relation
|
|
to the proposed research
|
|
|
|
o The adequacy of the proposed protection for humans, animals or the
|
|
environment, to the extent they may be adversely affected by the
|
|
project proposed in the application.
|
|
|
|
o The adequacy of the proposed plan to share data.
|
|
|
|
AWARD CRITERIA
|
|
|
|
Award criteria that will be used to make award decisions include:
|
|
|
|
o scientific merit (as determined by peer review)
|
|
o availability of funds
|
|
o programmatic priorities.
|
|
|
|
Applications will compete for available funds with all other
|
|
recommended applications. The following will be considered in making
|
|
funding decisions: Quality of the proposed project as determined by
|
|
peer review, availability of funds, and program priority.
|
|
|
|
INQUIRIES
|
|
|
|
Inquiries are encouraged. The opportunity to clarify issues or
|
|
questions from
|
|
potential applicants is welcome.
|
|
|
|
Direct inquiries regarding programmatic issues to:
|
|
|
|
Jonathan D. Pollock, Ph.D.
|
|
Division of Neuroscience and Behavioral Research
|
|
National Institute on Drug Abuse
|
|
6001 Executive Boulevard, Room 4282, MSC 9555
|
|
Bethesda, MD 20892-9555
|
|
Telephone: 301-443-6300
|
|
FAX: 301-594-6043
|
|
Email: <a href="/cdn-cgi/l/email-protection#b3d9c3828b80c1f3dddadb9dd4dcc5"><span class="__cf_email__" data-cfemail="7f150f4e474c0d3f11161751181009">[email protected]</span></a>
|
|
|
|
Direct inquiries regarding fiscal matters to:
|
|
|
|
Gary Fleming, J.D., M.A.
|
|
Grants Management Branch
|
|
National Institute on Drug Abuse
|
|
6001 Executive Boulevard, Room 3131, MSC 9541
|
|
Bethesda, MD 20892-9541
|
|
Telephone: 301-443-6710
|
|
FAX: 301-594-6847
|
|
Email: <a href="/cdn-cgi/l/email-protection#84e3e2b2f7c4eaedecaae3ebf2"><span class="__cf_email__" data-cfemail="8cebeabaffcce2e5e4a2ebe3fa">[email protected]</span></a>
|
|
|
|
AUTHORITY AND REGULATIONS
|
|
|
|
This program is described in the Catalog of Federal Domestic Assistance
|
|
No. 93.279. Awards are made under authorization of sections 301 and
|
|
405 of the Public Health Service Act as amended (42 USC 241 and 284)
|
|
and administered under NIH grants policies and Federal Regulations 42
|
|
CFR 52 and 45 CFR Parts 74 and 92. This program is not subject to the
|
|
intergovernmental review requirements of Executive Order 12372 or
|
|
Health Systems Agency review.
|
|
|
|
The PHS strongly encourages all grant and contract recipients to
|
|
provide a smoke-free workplace and promote the non-use of all tobacco
|
|
products. In addition, Public Law 103-227, the Pro-Children Act of
|
|
1994, prohibits smoking in certain facilities (or in some cases, and
|
|
portion of a facility) in which regular or routine education, library,
|
|
day care, health care or early childhood development services are
|
|
provided to children. This is consistent with the PHS mission to
|
|
protect and advance the physical and mental health of the
|
|
American people.
|
|
|
|
|
|
|
|
|
|
</pre>
|
|
|
|
<P><HR><P>
|
|
|
|
<A HREF="/grants/guide/WeeklyIndex.cfm?WeekEnding=10-19-01">Weekly TOC for this Announcement</A><br>
|
|
<A HREF="/grants/guide/index.html">NIH Funding Opportunities and Notices</A>
|
|
|
|
|
|
<!-- Start DHHSFooter.cfm 3/13/2008-->
|
|
<br><br>
|
|
<hr>
|
|
<table align="center">
|
|
<tr><td align="center" colspan="6"><span class='st_facebook_hcount' displayText='Facebook'></span>
|
|
<span class='st_twitter_hcount' displayText='Tweet'></span>
|
|
<span class='st_linkedin_hcount' displayText='LinkedIn'></span>
|
|
<span class='st_email_hcount' displayText='Email'></span>
|
|
<span class='st_sharethis_hcount' displayText='ShareThis'></span><br></td></tr>
|
|
<tr>
|
|
|
|
<td>
|
|
|
|
<div align="center"><a href="/grants/oer.htm"><img src="/images7/nih-oer-logo.jpg" alt="NIH Office of Extramural Research Logo" usemap="#Map2" border="0"></a></div>
|
|
|
|
<map name="Map2" id="Map2">
|
|
<area shape="rect" coords="89,17,359,39" href="http://www.nih.gov" />
|
|
<area shape="rect" coords="91,39,286,58" href="http://grants.nih.gov/grants/oer.htm" />
|
|
<area shape="rect" coords="3,5,78,55" href="http://grants.nih.gov/grants/oer.htm" />
|
|
</map>
|
|
|
|
</td>
|
|
|
|
<td width="20"> </td>
|
|
|
|
<td>
|
|
<a href="https://www.hhs.gov/"><img src="/images7/dhhs_sm.gif" width="36" height="37" border="0" alt="Department of Health and Human Services (HHS) - Home Page" long desc="Logo, circular in shape, depicting an American eagle in-flight with stylized profiles of human faces appearing on the trailing edge of the wings. The perimeter of the logo is encircled with the words 'Department of Health and Human Services U S A'"></a>
|
|
</td>
|
|
|
|
<td valign="middle">
|
|
<font size="-1" face="Arial">Department of Health<br>and Human Services (HHS)</font>
|
|
</td>
|
|
|
|
<td width="20"> </td>
|
|
|
|
<td>
|
|
<a href="https://www.usa.gov/"><img src="/images7/USA_Gov_logo.gif" border="0" alt="USA.gov - Government Made Easy" long desc="Logo,- the words 'USA.gov - Government Made Easy' with single streaking star above the logo"></a>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr align="center">
|
|
<td colspan="7">
|
|
</td>
|
|
</tr>
|
|
|
|
|
|
<tr align="center">
|
|
<td colspan="7">
|
|
<span style="color:#6E6E6E; font-size:1.0em; font-family: 'Trebuchet MS', Arial, Helvetica, sans-serif">NIH... Turning Discovery Into Health<sup>®</sup></span><br><br>
|
|
|
|
|
|
</td>
|
|
</tr>
|
|
|
|
</table>
|
|
<!-- End DHHSFooter.cfm 3/13/2008-->
|
|
|
|
<script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></BODY>
|
|
</HTML> |